<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>SM-6586 (SM) is a new derivative of <z:chebi fb="0" ids="50075">dihydropyridine</z:chebi> with potent calcium blocking activity and inhibitory activity of the <z:chebi fb="1" ids="29101">Na+</z:chebi>/H+ and <z:chebi fb="1" ids="29101">Na+</z:chebi>/<z:chebi fb="1" ids="39099">Ca+</z:chebi>+ exchange transport </plain></SENT>
<SENT sid="1" pm="."><plain>The effect of SM on survival rate, <z:hpo ids='HP_0002181'>brain edema</z:hpo> and metabolites was evaluated using two different models in spontaneously hypertensive rat (SHR) </plain></SENT>
<SENT sid="2" pm="."><plain>Global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was induced by bilateral common carotid artery ligation (BLCL) and focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The survival rate after BLCL was higher in the SM-treated group </plain></SENT>
<SENT sid="4" pm="."><plain>The brain water content was lower, the ATP level was higher and <z:chebi fb="4" ids="24996">lactate</z:chebi> level was lower in the SM-treated group compared to the control group </plain></SENT>
<SENT sid="5" pm="."><plain>In focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> models, the SM-treated group showed a reduction of T1 relaxation time </plain></SENT>
<SENT sid="6" pm="."><plain>The brain water content was significantly decreased in the SM-treated group </plain></SENT>
<SENT sid="7" pm="."><plain>These results indicate that SM was effective in ameliorating the ischemic insult in global and focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> models </plain></SENT>
</text></document>